Everything below concerns animal model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
In September 2025, Eucalyptus introduced an AI chatbot prompting warning from professional bodies about the use of artificial intelligence in weight-loss programs. In late December 2025, peak eating disorder advocacy groups expressed concerns about the rapid rollout of GLP-1 weight-loss treatments alongside their aggressive marketing on social media. There were concerns from The Australia and New Zealand Academy for Eating Disorders that these marketing techniques could target people who do not need the medication. Juniper's Black Friday sale was one of the marketing practices in question.
=== Bird decline === Besides the effects of direct consumption of insecticides, populations of insectivorous birds decline due to the collapse of their prey populations. Spraying of especially wheat and corn in Europe is believed to have caused an 80 per cent decline in flying insects, which in turn has reduced local bird populations by one to two thirds.
== Changes for the 2019 exam == For the 2019 exam, CBSE decided that vocational exams (which very few students take) would be held earlier, in mid/late February, rather than in March for most other exams. This was to ensure the exams were finished earlier. For many core subjects, the number of internal choices (where students pick one answer from two) was increased. The English (Core) paper of Class 12 was modified in a bid to make it less 'speedy'.
Sources: en.wikipedia.org
== Sponsorship and philanthropy == In 1972, Church's Chicken sponsored The San Antonio Church's Fried Chicken Inc. First International Chess Tournament, with a first prize of $4,000, resulting in the strongest chess tournament in the United States in 50 years. From 1979 to 1986, Church's Chicken sponsored the ChessCafe Grand Prix tournaments, under the auspices of the United States Chess Federation. Church's Partners Foundation, Inc. is a 501(c)(3) charity that supports the employees of franchisees of Church's Chicken, their families and their communities. The foundation awards $1,000 scholarships to American high school students through their Church's Scholars Program and awarded over $227,000 worth of scholarships in the 2018–2019 academic year. Church's Chicken has partnered with No Kid Hungry since 2016.
==== Corneal Allogenic Intrastromal Ring Segments (CAIRS) ==== Corneal Allogenic Intrastromal Ring Segments Keratoplasty (CAIRS Keratoplasty) represent an innovative surgical approach for the management of keratoconus, utilizing donor corneal tissue as biocompatible implants to reshape the ectatic cornea and improve visual acuity. CAIRS is a corneal transplant and due to its success rate, efficacy, safety profile and use of biologic tissue, it been recognised as such by funding bodies in Australia, the United Kingdom, Brazil, Japan, the Netherlands, Germany and numerous other countries. Unlike traditional synthetic intrastromal corneal ring segments (ICRS), which are typically made from polymethyl methacrylate (PMMA), CAIRS keratoplasty employs preserved allogeneic donor cornea to minimize risks such as extrusion, infection, or foreign body reactions associated with non-biological materials. The technique was developed by Soosan Jacob, who first described CAIRS in 2018 in a prospective interventional case series published in the Journal of Refractive Surgery. In this study, 24 eyes of 20 patients with keratoconus (grades 2–4) underwent CAIRS implantation combined with accelerated corneal collagen cross-linking (CXL). The procedure involved femtosecond laser-assisted creation of intrastromal tunnels followed by insertion of custom-cut allogeneic segments. Key outcomes included significant improvements in uncorrected distance visual acuity (UDVA) of 2.79 ± 2.65 lines and corrected distance visual acuity (CDVA) of 1.29 ± 1.33.
===== MeSH D08.811.464.938 – ubiquitin-protein ligase complexes ===== MeSH D08.811.464.938.249 – Ubiquitin-activating enzyme MeSH D08.811.464.938.500 – ubiquitin-conjugating enzymes MeSH D08.811.464.938.750 – ubiquitin-protein ligases MeSH D08.811.464.938.750.186 – fanconi anemia complementation group l protein MeSH D08.811.464.938.750.374 – proto-oncogene proteins c-cbl MeSH D08.811.464.938.750.562 – proto-oncogene proteins c-mdm2 MeSH D08.811.464.938.750.750 – skp cullin f-box protein ligases MeSH D08.811.464.938.750.750.500 – cullin proteins MeSH D08.811.464.938.750.875 – von hippel-lindau tumor suppressor protein
== Partnerships == Towards fulfilling its mandate, RCB is collaborating with various national and international institutions of repute. The partnerships are meant for exchange of ideas, information sharing, training, networking, conducting scientific colloquia, workshops, academic exchange programmes and student study visits within (and outside) India and for students of the Asia-Pacific region. RCB and National Institute of Advanced Industrial Science and Technology (AIST), Japan announced a partnership to further capacity building initiatives in bio-imaging and biotechnology. The agreement offers an excellent opportunity for both the institutions in capacity building, training and research collaborations, benefitting young scientists not only in India and Japan, but also from the UNESCO member countries in the Asia-Pacific and SAARC regions. In its continuing effort to fulfill the core mandate, RCB is actively engaged in a range of research and related activities in partnership with other academic institutions, which form part of the NCR Biotech Science Cluster, Faridabad. Shared facilities such as Advanced Technology Platform Centre (ATPC), and Bioincubators (supported by Biotechnology Industry Research Assistance Council (BIRAC)), which is meant to support the budding biotechnology entrepreneurs, are being established.
Sources: en.wikipedia.org
glycogen(n residues) + Pi ⇌ glycogen(n-1 residues) + glucose-1-phosphate Here, glycogen phosphorylase cleaves the bond linking a terminal glucose residue to a glycogen branch by substitution of a phosphoryl group for the α[1→4] linkage. Glucose-1-phosphate is converted to glucose-6-phosphate (which often ends up in glycolysis) by the enzyme phosphoglucomutase. Glucose residues are phosphorolysed from branches of glycogen until four residues before a glucose that is branched with a α[1→6] linkage. Glycogen debranching enzyme then transfers three of the remaining four glucose units to the end of another glycogen branch. This exposes the α[1→6] branching point, which is hydrolysed by α[1→6] glucosidase, removing the final glucose residue of the branch as a molecule of glucose and eliminating the branch. This is the only case in which a glycogen metabolite is not glucose-1-phosphate. The glucose is subsequently phosphorylated to glucose-6-phosphate by hexokinase.
The primary function of muscle tissue is contraction. The three types of muscle tissue (skeletal, cardiac and smooth) have significant differences. However, all three use the movement of actin against myosin to create contraction.
== Cultivation == The sacred lotus grows in water about 2.5 m (8 ft) to 30 cm (12 in) deep. In colder climates, a deeper water level protects the tubers more effectively, and improves growth and flowering. The sacred lotus germinates at temperatures above 13 °C (55 °F). Most varieties are not naturally cold-hardy, but may readily adapt to living outdoors year-round in USDA hardiness zones 6 through 11 (with some growers having success in zones as low as 4 or 5); the higher the zone's number, the greater the adaptability of the plants. In the growing season (from April to September in the northern hemisphere), the average daytime temperature needed is 23 to 27 °C (73 to 81 °F). In regions with low light levels in winter, the sacred lotus has a period of dormancy. The tubers are not cold-resistant if removed from water and exposed to the air; but when kept underwater in soil, the energy-rich tubers can overwinter temperatures below 0 °C (32 °F). If the plants are taken out of the water for wintertime storage (mostly in exceptionally cold climates), the tubers and roots must be stored in a stable, frost-free location, such as a garage, preferably in a cardboard box or container filled completely with vermiculite or perlite. Care must be taken to fully insulate the tubers.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.